title: Reliability and responsiveness of the Urgency Severity and Life Impact Questionnaire (USIQ).
abstract: OBJECTIVE
  The aims of this study are (1) to assess the reliability (test-retest) of the Urgency Severity and Life Impact Questionnaire (USIQ) and (2) to test the effect of extended-release tolterodine on symptoms of urinary urgency using this validated instrument.
  
  
  METHODS
  To measure reliability, women with overactive bladder (OAB) completed the USIQ on two separate occasions, prior to treatment for OAB. To assess the responsiveness, the USIQ participants completed the above-mentioned questionnaires prior to and following 4 weeks of treatment for OAB with extended-release tolterodine.
  
  
  RESULTS
  USIQ-S and USIQ-QoL scores at the two visits did not differ significantly. Repeated measures of USIQ-S and USIQ-QoL demonstrated a moderate to excellent intraclass correlation coefficient (0.64-0.74; P < 0.0001 and 0.48-0.91, P < 0.0001, respectively). A significant decrease in mean USIQ-S and USIQ-QOL (71 ± 14 vs. 44 ± 19, P < 0.0001 and 51 ± 22 vs. 39 ± 10, P < 0.01, respectively) scores following treatment with tolterodine.
  
  
  CONCLUSIONS
  This valid, reliable measure can be used in clinical practice and research trials to measure urgency severity.
authors.affiliation: Department of Obstetrics and Gynecology, Rambam Health Care Campus, Technion Faculty of Medicine, 8 Ha'aliya Street, Haifa 31096, Israel. lowensteinmd@gmail.com
authors.forename: Lior
authors.initials: L
authors.lastname: Lowenstein
authors.forename: Leslie
authors.initials: L
authors.lastname: Rickey
authors.forename: Kimberly
authors.initials: K
authors.lastname: Kenton
authors.forename: Mary P
authors.initials: MP
authors.lastname: Fitzgerald
authors.forename: Linda
authors.initials: L
authors.lastname: Brubaker
authors.forename: Mary
authors.initials: M
authors.lastname: Tulke
authors.forename: Joye
authors.initials: J
authors.lastname: Fordham
authors.forename: Elizabeth R
authors.initials: ER
authors.lastname: Mueller
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001559:Benzhydryl Compounds / Q000627:therapeutic use; D003408:Cresols / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008875:Middle Aged; D018727:Muscarinic Antagonists / Q000627:therapeutic use; D010665:Phenylpropanolamine / Q000627:therapeutic use; D011788:Quality of Life; D015203:Reproducibility of Results; D012720:Severity of Illness Index; D011795:Surveys and Questionnaires; D000068737:Tolterodine Tartrate; D053201:Urinary Bladder, Overactive / Q000188:drug therapy / Q000503:physiopathology*
chemical_list: D001559:Benzhydryl Compounds; D003408:Cresols; D018727:Muscarinic Antagonists; D010665:Phenylpropanolamine; D000068737:Tolterodine Tartrate